ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS

In preclinical studies we have defined IDH1R132H as a clonal neoantigen presented on MHC class II. A peptide vaccine encompassing IDH1R132H induces tumor-specific T helper cell responses effective in controlling syngeneic IDH1R132H-mutant tumors in humanized mouse models. NOA-16 (NCT02454634) is a f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Platten, Michael, Schilling, Daniela, Bunse, Lukas, Wick, Antje, Bunse, Theresa, Riehl, Dennis, Green, Edward, Sanghvi, Khwab, Karapanagiotou-Schenkel, Irini, Harting, Inga, Sahm, Felix, Steinbach, Joachim, Weyerbrock, Astrid, Hense, Jörg, Misch, Martin, Krex, Dietmar, Stevanovic, Stefan, Tabatabai, Ghazaleh, von Deimling, Andreas, Schmitt, Michael, Wick, Wolfgang
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216146/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.028
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados